Mortality impact of less-than-standard therapy in older breast cancer patients

The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disea...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the American College of Surgeons Ročník 206; číslo 1; s. 66
Hlavní autoři:	Yood, Marianne Ulcickas, Owusu, Cynthia, Buist, Diana S M, Geiger, Ann M, Field, Terry S, Thwin, Soe Soe, Lash, Timothy L, Prout, Marianne N, Wei, Feifei, Quinn, Virginia P, Frost, Floyd J, Silliman, Rebecca A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.01.2008
Témata:	Aged Aged, 80 and over Antineoplastic Agents, Hormonal - therapeutic use Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Female Follow-Up Studies Humans Mastectomy - methods Neoplasm Staging Proportional Hazards Models Radiotherapy, Adjuvant - methods Retrospective Studies Survival Rate - trends Tamoxifen - therapeutic use Treatment Outcome United States - epidemiology United States
ISSN:	1879-1190, 1879-1190
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disease. This cohort study was conducted within six US integrated health-care delivery systems. Automated administrative databases, medical records, and tumor registries were used to identify women aged 65 years or older who received BCS or mastectomy to treat stage I or II breast cancer diagnosed from January 1, 1990, through December 31, 1994. We compared cause-specific 10-year mortality rates across treatment categories by fitting Cox proportional hazards models adjusted for demographics and tumor characteristics. We identified 1,837 women having operations for stage I or II breast cancer. Compared with women receiving mastectomy, those receiving BCS without RT were twice as likely to die of breast cancer (adjusted hazards ratio [HR]=2.19, 95% confidence interval [CI], 1.51 to 3.18). Breast cancer mortality rates were similar between women receiving BCS plus RT and women receiving mastectomy (adjusted HR=1.08, 95% CI, 0.79 to 1.48). In the subset of 886 chemotherapy-naive women treated with tamoxifen, those treated with tamoxifen for less than 1 year had a substantially higher breast cancer mortality rate than those exposed 5 years or more (adjusted HR=6.26, 95% CI, 3.10 to 12.64). Our findings indicate that older women receiving BCS alone have higher rates of breast cancer death than those receiving BCS + RT or mastectomy and that the survival benefit from tamoxifen increases with increasing duration of treatment.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1879-1190 1879-1190
DOI:	10.1016/j.jamcollsurg.2007.07.015